toxylact: a02bx77 gerafnate with psycholeptics

The first professional lActological database in the word

Gefarnate combinations with psycholeptics (ATC A02BX77) are considered clinically obsolete and are entirely unsuitable during breastfeeding because the psycholeptic component determines an unacceptably high lactation risk despite gefarnate itself being compatible with lactation.file+2

ATC class and indication

Gefarnate is a gastroprotective, anti‑ulcer drug used in the treatment of gastric and duodenal ulcers and gastritis, facilitating healing and function of the gastrointestinal mucosa. Within the ATC system it belongs to A02BX (other drugs for peptic ulcer and gastro‑oesophageal reflux disease), and A02BX77 designates “Gefarnate, combinations with psycholeptics.”wikipedia+7

Preparations in class A02BX77 combine gefarnate with one or more psycholeptic agents (for example sedative, anxiolytic or antipsychotic components) to enhance the anti‑ulcer effect. These combinations are intended for peptic ulcer disease of the stomach or duodenum and related acid‑related disorders, but currently have limited or no use in many markets.drugbank+2

Availability and regulatory status

Gefarnate as a single substance (A02BX07) has been or is marketed in several Asian markets, mainly as tablets or capsules. In contrast, gefarnate–psycholeptic fixed combinations (A02BX77) appear to be rare or absent from contemporary formularies, reflecting changing risk–benefit assessment and availability of safer anti‑ulcer regimens.mims+6

On the referenced Bulgarian toxicology‑lactation site it is explicitly noted that no medicinal products of class A02BX77 are currently registered in Bulgaria. This underscores their marginal practical relevance today and supports approaching them mainly as a theoretical toxicological entity in modern clinical practice.bda+1

Mechanism of action

Gefarnate is a water‑insoluble terpene fatty acid with gastroprotective properties, enhancing healing and function of mucosal tissue. It strengthens the gastrointestinal mucosal barrier by stimulating mucus and bicarbonate production and promoting prostaglandin‑mediated mucosal blood flow and tissue repair.synapse.patsnap+3

Psycholeptic components can provide additional symptom relief (for example, anxiolysis, sedation, modulation of visceral perception), which historically was thought to potentiate the overall anti‑ulcer effect. However, their central nervous system (CNS) activity, sedative potential and often long half‑lives dominate the safety profile, particularly in vulnerable populations.medpedia.framar+1

General toxicological profile

Gefarnate itself is generally regarded as a relatively low‑toxicity gastroprotective agent with adverse effects primarily related to mild gastrointestinal discomfort. It lacks significant systemic toxicity at therapeutic doses, and no major organ‑specific toxicity has been highlighted in standard reference descriptions.echemi+3

Psycholeptics, in contrast, encompass a broad group of CNS‑depressant drugs (for example, benzodiazepines, barbiturates, certain antipsychotics or sedative antidepressants), which carry risks of sedation, respiratory depression, hypotension, extrapyramidal reactions, and cognitive impairment, especially with chronic use or in overdose. When combined in a fixed formulation, the overall toxicological risk of an A02BX77 product must be judged by the most hazardous component, which in this case is the psycholeptic.ncbi.nlm.nih+2

Toxicological risk in pregnancy

For gefarnate itself, pregnancy safety data are limited and an official FDA pregnancy category has not been assigned. The absence of robust human data necessitates a cautious, individualized risk–benefit assessment if use during pregnancy is considered.drugcentral+2

Psycholeptics as a class are associated with potential teratogenicity or neonatal adaptation issues depending on the specific substance, dose and timing (for example, neonatal respiratory depression, withdrawal, hypotonia or neurologic symptoms). Therefore, for combination products in A02BX77, pregnancy risk should again be guided by the psycholeptic component, generally discouraging their use unless clearly justified and no safer alternatives exist.file+1

Lactation risk and lactation category

On the cited lactation‑focused Bulgarian reference site, gefarnate monotherapy is described as fully compatible with breastfeeding. However, when combined with psycholeptics in class A02BX77, the preparations are classified as Toxico‑lactation Category IV, defined there as completely unsuitable for use during lactation.file

The rationale is that psycholeptic agents tend to be lipophilic, often with substantial oral bioavailability in the infant and significant CNS penetration, so even modest transfer into breast milk can induce sedation, hypotonia, feeding difficulties and impaired arousal in the breastfed infant. As a result, the overall lactation safety of the combination must be determined by the least acceptable ingredient, i.e. the psycholeptic, making the entire A02BX77 class contraindicated during breastfeeding despite gefarnate itself being lactation‑compatible.ncbi.nlm.nih+1

Clinical recommendations in breastfeeding

Because of the high theoretical and practical risk posed by psycholeptic components, use of gefarnate–psycholeptic combinations (A02BX77) should be avoided entirely in breastfeeding women. If a lactating patient requires gastroprotective therapy, safer alternatives such as proton‑pump inhibitors, H2‑receptor antagonists or gefarnate monotherapy (where available and assessed as compatible) should be preferred according to up‑to‑date lactation references and local guidelines.synapse.patsnap+3

When a woman has been unintentionally exposed to an A02BX77 product during lactation, clinical monitoring of the infant is mandatory, focusing on level of consciousness, feeding, weight gain, respiratory pattern and neuromotor behavior. In cases of significant or repeated exposure, temporary interruption of breastfeeding and substitution with stored milk or formula may be warranted, guided by specialist consultation in toxicology or clinical pharmacology.ncbi.nlm.nih

Summary for practice

Gefarnate–psycholeptic combinations (ATC A02BX77) are historical or marginally used anti‑ulcer preparations whose safety profile is dominated by their psycholeptic component. While gefarnate alone is considered low‑toxicity and compatible with breastfeeding, the addition of a psycholeptic renders these fixed combinations entirely inappropriate for lactating women and questionable in pregnancy, particularly given the availability of safer alternatives.drugbank+5

In Bulgaria, no A02BX77 medicinal products are currently registered, which practically limits their clinical use locally, but they remain relevant as a toxicological and lactation‑risk category in reference systems. For any gastroprotective need in breastfeeding patients, clinicians should avoid A02BX77 products, consult dedicated lactation databases, and choose agents with well‑characterized, favorable lactation safety profiles.bda+2

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.